ID   GARS_HUMAN              Reviewed;         739 AA.
AC   P41250; B3KQA2; B4DIA0; Q969Y1;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   10-MAY-2017, entry version 180.
DE   RecName: Full=Glycine--tRNA ligase;
DE            EC=3.6.1.17 {ECO:0000269|PubMed:19710017};
DE            EC=6.1.1.14 {ECO:0000269|PubMed:17544401};
DE   AltName: Full=Diadenosine tetraphosphate synthetase;
DE            Short=AP-4-A synthetase;
DE   AltName: Full=Glycyl-tRNA synthetase;
DE            Short=GlyRS;
GN   Name=GARS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-42.
RX   PubMed=7962006;
RA   Shiba K., Schimmel P., Motegi H., Noda T.;
RT   "Human glycyl-tRNA synthetase. Wide divergence of primary structure
RT   from bacterial counterpart and species-specific aminoacylation.";
RL   J. Biol. Chem. 269:30049-30055(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-42.
RX   PubMed=7753621; DOI=10.1093/nar/23.8.1307;
RA   Williams J.H., Osvath S.R., Khong T.-F., Pearse M.J., Power D.A.;
RT   "Cloning, sequencing and bacterial expression of human glycine tRNA
RT   synthetase.";
RL   Nucleic Acids Res. 23:1307-1310(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-42.
RC   TISSUE=Embryo, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-42.
RC   TISSUE=Eye, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-739, AND VARIANT ALA-42.
RX   PubMed=7961834;
RA   Ge Q., Trieu E.P., Targoff I.N.;
RT   "Primary structure and functional expression of human glycyl-tRNA
RT   synthetase, an autoantigen in myositis.";
RL   J. Biol. Chem. 269:28790-28797(1994).
RN   [7]
RP   SUBCELLULAR LOCATION, VARIANTS CMT2D GLY-125 AND ARG-294,
RP   CHARACTERIZATION OF VARIANTS CMT2D GLY-125 AND ARG-294, VARIANTS HMN5A
RP   PRO-183; ARG-472 AND ARG-580, AND CHARACTERIZATION OF VARIANTS HMN5A
RP   PRO-183; ARG-472 AND ARG-580.
RX   PubMed=17035524; DOI=10.1523/JNEUROSCI.1671-06.2006;
RA   Antonellis A., Lee-Lin S.Q., Wasterlain A., Leo P., Quezado M.,
RA   Goldfarb L.G., Myung K., Burgess S., Fischbeck K.H., Green E.D.;
RT   "Functional analyses of glycyl-tRNA synthetase mutations suggest a key
RT   role for tRNA-charging enzymes in peripheral axons.";
RL   J. Neurosci. 26:10397-10406(2006).
RN   [8]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-204 AND LYS-501, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35 AND THR-736, VARIANT
RP   [LARGE SCALE ANALYSIS] ALA-42, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   SUBCELLULAR LOCATION, VARIANTS CMT2D VAL-111; ASN-200; PHE-265;
RP   ARG-294; LEU-298; PHE-334; ARG-472; ASN-554; ARG-580 AND ALA-652,
RP   VARIANT LEU-635, CHARACTERIZATION OF VARIANTS CMT2D VAL-111; GLY-125;
RP   PRO-183; ASN-200; PHE-265; ARG-294; LEU-298; PHE-334; ARG-472;
RP   ASN-554; ARG-580 AND ALA-652, AND CHARACTERIZATION OF VARIANT LEU-635.
RX   PubMed=25168514; DOI=10.1002/humu.22681;
RA   Griffin L.B., Sakaguchi R., McGuigan D., Gonzalez M.A., Searby C.,
RA   Zuchner S., Hou Y.M., Antonellis A.;
RT   "Impaired function is a common feature of neuropathy-associated
RT   glycyl-tRNA synthetase mutations.";
RL   Hum. Mutat. 35:1363-1371(2014).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 55-739, FUNCTION, SUBUNIT,
RP   CHARACTERIZATION OF VARIANT LEU-635, CATALYTIC ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17544401; DOI=10.1016/j.febslet.2007.05.046;
RA   Cader M.Z., Ren J., James P.A., Bird L.E., Talbot K., Stammers D.K.;
RT   "Crystal structure of human wildtype and S581L-mutant glycyl-tRNA
RT   synthetase, an enzyme underlying distal spinal muscular atrophy.";
RL   FEBS Lett. 581:2959-2964(2007).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 55-739, VARIANT ARG-580, AND
RP   SUBUNIT.
RX   PubMed=17545306; DOI=10.1073/pnas.0703908104;
RA   Xie W., Nangle L.A., Zhang W., Schimmel P., Yang X.-L.;
RT   "Long-range structural effects of a Charcot-Marie-Tooth disease-
RT   causing mutation in human glycyl-tRNA synthetase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:9976-9981(2007).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 55-739 IN COMPLEX WITH ATP;
RP   SUBSTRATE AND SUBSTRATE ANALOGS, AND FUNCTION.
RX   PubMed=19710017; DOI=10.1074/jbc.M109.030692;
RA   Guo R.-T., Chong Y.E., Guo M., Yang X.-L.;
RT   "Crystal structures and biochemical analyses suggest a unique
RT   mechanism and role for human glycyl-tRNA synthetase in Ap4A
RT   homeostasis.";
RL   J. Biol. Chem. 284:28968-28976(2009).
RN   [17]
RP   VARIANTS CMT2D GLY-125 AND ARG-294, VARIANTS HMN5A PRO-183 AND
RP   ARG-580, AND TISSUE SPECIFICITY.
RX   PubMed=12690580; DOI=10.1086/375039;
RA   Antonellis A., Ellsworth R.E., Sambuughin N., Puls I., Abel A.,
RA   Lee-Lin S.Q., Jordanova A., Kremensky I., Christodoulou K.,
RA   Middleton L.T., Sivakumar K., Ionasescu V., Funalot B., Vance J.M.,
RA   Goldfarb L.G., Fischbeck K.H., Green E.D.;
RT   "Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type
RT   2D and distal spinal muscular atrophy type V.";
RL   Am. J. Hum. Genet. 72:1293-1299(2003).
RN   [18]
RP   VARIANT HMN5A ARG-472.
RX   PubMed=24627108; DOI=10.1007/s00415-014-7289-8;
RA   Schabhuettl M., Wieland T., Senderek J., Baets J., Timmerman V.,
RA   De Jonghe P., Reilly M.M., Stieglbauer K., Laich E., Windhager R.,
RA   Erwa W., Trajanoski S., Strom T.M., Auer-Grumbach M.;
RT   "Whole-exome sequencing in patients with inherited neuropathies:
RT   outcome and challenges.";
RL   J. Neurol. 261:970-982(2014).
RN   [19]
RP   VARIANTS CMT2D TYR-200 AND ARG-292.
RX   PubMed=26244500; DOI=10.1371/journal.pone.0133423;
RA   Liao Y.C., Liu Y.T., Tsai P.C., Chang C.C., Huang Y.H., Soong B.W.,
RA   Lee Y.C.;
RT   "Two novel de novo gars mutations cause early-onset axonal Charcot-
RT   Marie-tooth disease.";
RL   PLoS ONE 10:E0133423-E0133423(2015).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS CMT2D GLY-125 AND ARG-294, AND
RP   CHARACTERIZATION OF VARIANT HMN5A PRO-183.
RX   PubMed=26503042; DOI=10.1038/nature15510;
RA   He W., Bai G., Zhou H., Wei N., White N.M., Lauer J., Liu H., Shi Y.,
RA   Dumitru C.D., Lettieri K., Shubayev V., Jordanova A.,
RA   Guergueltcheva V., Griffin P.R., Burgess R.W., Pfaff S.L., Yang X.L.;
RT   "CMT2D neuropathy is linked to the neomorphic binding activity of
RT   glycyl-tRNA synthetase.";
RL   Nature 526:710-714(2015).
RN   [21]
RP   ERRATUM.
RX   PubMed=26789244; DOI=10.1038/nature16499;
RA   He W., Bai G., Zhou H., Wei N., White N.M., Lauer J., Liu H., Shi Y.,
RA   Dan Dumitru C., Lettieri K., Shubayev V., Jordanova A.,
RA   Guergueltcheva V., Griffin P.R., Burgess R.W., Pfaff S.L., Yang X.L.;
RT   "Corrigendum: CMT2D neuropathy is linked to the neomorphic binding
RT   activity of glycyl-tRNA synthetase.";
RL   Nature 532:402-402(2016).
CC   -!- FUNCTION: Catalyzes the ligation of glycine to the 3'-end of its
CC       cognate tRNA. Also produces diadenosine tetraphosphate (Ap4A), a
CC       universal pleiotropic signaling molecule needed for cell
CC       regulation pathways, by direct condensation of 2 ATPs.
CC       {ECO:0000269|PubMed:17544401, ECO:0000269|PubMed:19710017}.
CC   -!- CATALYTIC ACTIVITY: ATP + glycine + tRNA(Gly) = AMP + diphosphate
CC       + glycyl-tRNA(Gly). {ECO:0000269|PubMed:17544401}.
CC   -!- CATALYTIC ACTIVITY: P(1),P(4)-bis(5'-guanosyl) tetraphosphate +
CC       H(2)O = GTP + GMP. {ECO:0000269|PubMed:19710017}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.3 uM for tRNA(Gly(GCC)) {ECO:0000269|PubMed:17544401};
CC         KM=15 uM for glycine {ECO:0000269|PubMed:17544401};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:17544401,
CC       ECO:0000269|PubMed:17545306, ECO:0000269|PubMed:19710017}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17035524}.
CC       Cell projection, axon {ECO:0000269|PubMed:17035524,
CC       ECO:0000269|PubMed:25168514}. Secreted
CC       {ECO:0000250|UniProtKB:Q9CZD3}. Secreted, exosome
CC       {ECO:0000250|UniProtKB:Q9CZD3}. Note=Secreted by motor neuron,
CC       possibly through the exosome pathway (By similarity). In
CC       transfected COS7 cells, not detected in mitochondria, nor in Golgi
CC       apparatus (PubMed:17035524). {ECO:0000250|UniProtKB:Q9CZD3,
CC       ECO:0000269|PubMed:17035524}.
CC   -!- TISSUE SPECIFICITY: Widely expressed, including in brain and
CC       spinal cord. {ECO:0000269|PubMed:12690580}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2D (CMT2D) [MIM:601472]: A
CC       dominant axonal form of Charcot-Marie-Tooth disease, a disorder of
CC       the peripheral nervous system, characterized by progressive
CC       weakness and atrophy, initially of the peroneal muscles and later
CC       of the distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited)
CC       and primary peripheral axonal neuropathies (CMT2). Neuropathies of
CC       the CMT2 group are characterized by signs of axonal degeneration
CC       in the absence of obvious myelin alterations, normal or slightly
CC       reduced nerve conduction velocities, and progressive distal muscle
CC       weakness and atrophy. Nerve conduction velocities are normal or
CC       slightly reduced. {ECO:0000269|PubMed:12690580,
CC       ECO:0000269|PubMed:17035524, ECO:0000269|PubMed:25168514,
CC       ECO:0000269|PubMed:26244500, ECO:0000269|PubMed:26503042}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry. Contrary to the wild-type protein,
CC       CMT2D variants Gly-125 and Arg-294 strongly interact with NRP1.
CC       This interaction may compete out VEGFA binding and inhibits VEGFA-
CC       NRP1 signling which is essential for motor neuron survival, as
CC       suggested by experiments done in a mouse model.
CC       {ECO:0000269|PubMed:26503042}.
CC   -!- DISEASE: Neuronopathy, distal hereditary motor, 5A (HMN5A)
CC       [MIM:600794]: A disorder characterized by distal muscular atrophy
CC       mainly affecting the upper extremities, in contrast to other
CC       distal motor neuronopathies. These constitute a heterogeneous
CC       group of neuromuscular diseases caused by selective degeneration
CC       of motor neurons in the anterior horn of the spinal cord, without
CC       sensory deficit in the posterior horn. The overall clinical
CC       picture consists of a classical distal muscular atrophy syndrome
CC       in the legs without clinical sensory loss. The disease starts with
CC       weakness and wasting of distal muscles of the anterior tibial and
CC       peroneal compartments of the legs. Later on, weakness and atrophy
CC       may expand to the proximal muscles of the lower limbs and/or to
CC       the distal upper limbs. {ECO:0000269|PubMed:12690580,
CC       ECO:0000269|PubMed:17035524, ECO:0000269|PubMed:24627108,
CC       ECO:0000269|PubMed:26503042}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Contrary
CC       to the wild-type protein, HMN5A variant Pro-183 strongly interacts
CC       with NRP1. This interaction may compete out VEGFA binding and
CC       inhibits VEGFA-NRP1 signling which is essential for motor neuron
CC       survival, as suggested by experiments done in a mouse model.
CC       {ECO:0000269|PubMed:26503042}.
CC   -!- SIMILARITY: Belongs to the class-II aminoacyl-tRNA synthetase
CC       family. {ECO:0000305}.
CC   -!- CAUTION: According to a report, variant Leu-635 induces reduced
CC       activity (PubMed:17544401). According to another report, it does
CC       not affect function (PubMed:25168514).
CC       {ECO:0000269|PubMed:17544401, ECO:0000269|PubMed:25168514}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA57001.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAA86443.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Inherited peripheral neuropathies mutation db;
CC       URL="http://www.molgen.ua.ac.be/CMTMutations/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D30658; BAA06338.1; -; mRNA.
DR   EMBL; U09510; AAA86443.1; ALT_INIT; mRNA.
DR   EMBL; AK074524; BAG51964.1; -; mRNA.
DR   EMBL; AK295490; BAG58412.1; -; mRNA.
DR   EMBL; AC005154; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006969; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004976; AAC71652.1; -; Genomic_DNA.
DR   EMBL; BC007722; AAH07722.1; -; mRNA.
DR   EMBL; BC007755; AAH07755.1; -; mRNA.
DR   EMBL; U09587; AAA57001.1; ALT_INIT; mRNA.
DR   CCDS; CCDS43564.1; -.
DR   PIR; A55314; A55314.
DR   RefSeq; NP_001303701.1; NM_001316772.1.
DR   RefSeq; NP_002038.2; NM_002047.3.
DR   UniGene; Hs.404321; -.
DR   PDB; 2PME; X-ray; 2.90 A; A=55-739.
DR   PDB; 2PMF; X-ray; 2.85 A; A=55-739.
DR   PDB; 2Q5H; X-ray; 3.00 A; A=55-739.
DR   PDB; 2Q5I; X-ray; 2.80 A; A=55-739.
DR   PDB; 2ZT5; X-ray; 2.50 A; A=55-739.
DR   PDB; 2ZT6; X-ray; 3.08 A; A=55-739.
DR   PDB; 2ZT7; X-ray; 2.70 A; A=55-739.
DR   PDB; 2ZT8; X-ray; 3.35 A; A=55-739.
DR   PDB; 2ZXF; X-ray; 3.40 A; A=55-739.
DR   PDB; 4KQE; X-ray; 2.74 A; A=55-739.
DR   PDB; 4KR2; X-ray; 3.29 A; A=114-739.
DR   PDB; 4KR3; X-ray; 3.24 A; A=114-739.
DR   PDB; 4QEI; X-ray; 2.88 A; A=118-739.
DR   PDB; 5E6M; X-ray; 2.93 A; A/B=55-739.
DR   PDBsum; 2PME; -.
DR   PDBsum; 2PMF; -.
DR   PDBsum; 2Q5H; -.
DR   PDBsum; 2Q5I; -.
DR   PDBsum; 2ZT5; -.
DR   PDBsum; 2ZT6; -.
DR   PDBsum; 2ZT7; -.
DR   PDBsum; 2ZT8; -.
DR   PDBsum; 2ZXF; -.
DR   PDBsum; 4KQE; -.
DR   PDBsum; 4KR2; -.
DR   PDBsum; 4KR3; -.
DR   PDBsum; 4QEI; -.
DR   PDBsum; 5E6M; -.
DR   ProteinModelPortal; P41250; -.
DR   SMR; P41250; -.
DR   BioGrid; 108887; 89.
DR   DIP; DIP-50471N; -.
DR   IntAct; P41250; 19.
DR   MINT; MINT-1395438; -.
DR   STRING; 9606.ENSP00000373918; -.
DR   DrugBank; DB00145; Glycine.
DR   iPTMnet; P41250; -.
DR   PhosphoSitePlus; P41250; -.
DR   SwissPalm; P41250; -.
DR   BioMuta; GARS; -.
DR   DMDM; 313104283; -.
DR   EPD; P41250; -.
DR   MaxQB; P41250; -.
DR   PaxDb; P41250; -.
DR   PeptideAtlas; P41250; -.
DR   PRIDE; P41250; -.
DR   DNASU; 2617; -.
DR   Ensembl; ENST00000389266; ENSP00000373918; ENSG00000106105.
DR   GeneID; 2617; -.
DR   KEGG; hsa:2617; -.
DR   UCSC; uc003tbm.4; human.
DR   CTD; 2617; -.
DR   DisGeNET; 2617; -.
DR   GeneCards; GARS; -.
DR   GeneReviews; GARS; -.
DR   H-InvDB; HIX0006570; -.
DR   HGNC; HGNC:4162; GARS.
DR   HPA; HPA017896; -.
DR   HPA; HPA019097; -.
DR   MalaCards; GARS; -.
DR   MIM; 600287; gene.
DR   MIM; 600794; phenotype.
DR   MIM; 601472; phenotype.
DR   neXtProt; NX_P41250; -.
DR   OpenTargets; ENSG00000106105; -.
DR   Orphanet; 99938; Autosomal dominant Charcot-Marie-Tooth disease type 2D.
DR   Orphanet; 139536; Distal hereditary motor neuropathy type 5.
DR   PharmGKB; PA28575; -.
DR   eggNOG; KOG2298; Eukaryota.
DR   eggNOG; COG0423; LUCA.
DR   GeneTree; ENSGT00390000016949; -.
DR   HOGENOM; HOG000242015; -.
DR   HOVERGEN; HBG036190; -.
DR   InParanoid; P41250; -.
DR   KO; K01880; -.
DR   OMA; ERFGWVE; -.
DR   OrthoDB; EOG091G02U0; -.
DR   PhylomeDB; P41250; -.
DR   TreeFam; TF343504; -.
DR   BRENDA; 6.1.1.14; 2681.
DR   Reactome; R-HSA-379716; Cytosolic tRNA aminoacylation.
DR   Reactome; R-HSA-379726; Mitochondrial tRNA aminoacylation.
DR   ChiTaRS; GARS; human.
DR   EvolutionaryTrace; P41250; -.
DR   GeneWiki; Glycine%E2%80%94tRNA_ligase; -.
DR   GenomeRNAi; 2617; -.
DR   PMAP-CutDB; P41250; -.
DR   PRO; PR:P41250; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106105; -.
DR   CleanEx; HS_GARS; -.
DR   ExpressionAtlas; P41250; baseline and differential.
DR   Genevisible; P41250; HS.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004081; F:bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activity; IDA:UniProtKB.
DR   GO; GO:0004820; F:glycine-tRNA ligase activity; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:UniProtKB.
DR   GO; GO:0015966; P:diadenosine tetraphosphate biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006426; P:glycyl-tRNA aminoacylation; IBA:GO_Central.
DR   GO; GO:0006418; P:tRNA aminoacylation for protein translation; TAS:Reactome.
DR   CDD; cd00774; GlyRS-like_core; 1.
DR   Gene3D; 3.40.50.800; -; 1.
DR   InterPro; IPR002314; aa-tRNA-synt_IIb.
DR   InterPro; IPR006195; aa-tRNA-synth_II.
DR   InterPro; IPR004154; Anticodon-bd.
DR   InterPro; IPR027031; Gly-tRNA_synthase/POLG2.
DR   InterPro; IPR033731; GlyRS-like_core.
DR   InterPro; IPR009068; S15_NS1_RNA-bd.
DR   InterPro; IPR002315; tRNA-synt_gly.
DR   InterPro; IPR000738; WHEP-TRS_dom.
DR   PANTHER; PTHR10745; PTHR10745; 1.
DR   Pfam; PF03129; HGTP_anticodon; 1.
DR   Pfam; PF00587; tRNA-synt_2b; 1.
DR   Pfam; PF00458; WHEP-TRS; 1.
DR   PRINTS; PR01043; TRNASYNTHGLY.
DR   SMART; SM00991; WHEP-TRS; 1.
DR   SUPFAM; SSF47060; SSF47060; 1.
DR   SUPFAM; SSF52954; SSF52954; 1.
DR   TIGRFAMs; TIGR00389; glyS_dimeric; 1.
DR   PROSITE; PS50862; AA_TRNA_LIGASE_II; 1.
DR   PROSITE; PS00762; WHEP_TRS_1; 1.
DR   PROSITE; PS51185; WHEP_TRS_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Aminoacyl-tRNA synthetase; ATP-binding;
KW   Cell projection; Charcot-Marie-Tooth disease; Complete proteome;
KW   Cytoplasm; Disease mutation; Hydrolase; Ligase; Neurodegeneration;
KW   Neuropathy; Nucleotide-binding; Phosphoprotein; Protein biosynthesis;
KW   Reference proteome; Secreted.
FT   CHAIN         1    739       Glycine--tRNA ligase.
FT                                /FTId=PRO_0000072998.
FT   DOMAIN       63    119       WHEP-TRS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00531}.
FT   NP_BIND     331    333       ATP. {ECO:0000269|PubMed:19710017}.
FT   NP_BIND     341    346       ATP. {ECO:0000269|PubMed:19710017}.
FT   NP_BIND     457    458       ATP. {ECO:0000269|PubMed:19710017}.
FT   NP_BIND     580    583       ATP. {ECO:0000269|PubMed:19710017}.
FT   REGION      346    350       Substrate binding.
FT   REGION      576    580       Substrate binding.
FT   BINDING     213    213       Substrate. {ECO:0000269|PubMed:19710017}.
FT   BINDING     299    299       Substrate. {ECO:0000269|PubMed:19710017}.
FT   BINDING     435    435       Substrate; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:19710017}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     204    204       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     453    453       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9CZD3}.
FT   MOD_RES     501    501       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     700    700       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9CZD3}.
FT   MOD_RES     736    736       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      42     42       P -> A (in dbSNP:rs1049402).
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7753621,
FT                                ECO:0000269|PubMed:7961834,
FT                                ECO:0000269|PubMed:7962006}.
FT                                /FTId=VAR_054865.
FT   VARIANT     111    111       A -> V (in CMT2D; shows a reduction in
FT                                aminoacylation activity;
FT                                dbSNP:rs370531212).
FT                                {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073187.
FT   VARIANT     125    125       E -> G (in CMT2D; phenotype overlapping
FT                                with DSMA-V; complements the defect of
FT                                the wild-type gene in yeast; contrary to
FT                                the wild-type protein, strongly binds to
FT                                NRP1 and competes with VEGFA for NRP1-
FT                                binding; dbSNP:rs28936972).
FT                                {ECO:0000269|PubMed:12690580,
FT                                ECO:0000269|PubMed:17035524,
FT                                ECO:0000269|PubMed:25168514,
FT                                ECO:0000269|PubMed:26503042}.
FT                                /FTId=VAR_018718.
FT   VARIANT     183    183       L -> P (in HMN5A; does not complement the
FT                                defect of the wild-type gene in yeast;
FT                                contrary to the wild-type protein,
FT                                strongly interacts with NRP1;
FT                                dbSNP:rs137852644).
FT                                {ECO:0000269|PubMed:12690580,
FT                                ECO:0000269|PubMed:17035524,
FT                                ECO:0000269|PubMed:25168514,
FT                                ECO:0000269|PubMed:26503042}.
FT                                /FTId=VAR_018719.
FT   VARIANT     200    200       D -> N (in CMT2D; shows a large reduction
FT                                in aminoacylation activity).
FT                                {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073188.
FT   VARIANT     200    200       D -> Y (in CMT2D).
FT                                {ECO:0000269|PubMed:26244500}.
FT                                /FTId=VAR_074016.
FT   VARIANT     265    265       S -> F (in CMT2D; shows a large reduction
FT                                in aminoacylation activity; demonstrates
FT                                a change in the subcellular location
FT                                pattern; does not associate with
FT                                granules). {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073189.
FT   VARIANT     268    268       T -> I (in dbSNP:rs2230310).
FT                                /FTId=VAR_054866.
FT   VARIANT     292    292       M -> R (in CMT2D).
FT                                {ECO:0000269|PubMed:26244500}.
FT                                /FTId=VAR_074017.
FT   VARIANT     294    294       G -> R (in CMT2D; shows a large reduction
FT                                in aminoacylation activity; does not
FT                                impair transcription or translation or
FT                                protein stability; contrary to the wild-
FT                                type protein, strongly interacts with
FT                                NRP1; dbSNP:rs137852643).
FT                                {ECO:0000269|PubMed:12690580,
FT                                ECO:0000269|PubMed:17035524,
FT                                ECO:0000269|PubMed:25168514,
FT                                ECO:0000269|PubMed:26503042}.
FT                                /FTId=VAR_018720.
FT   VARIANT     298    298       P -> L (in CMT2D; shows a large reduction
FT                                in aminoacylation activity; demonstrates
FT                                a change in subcellular location pattern;
FT                                does not associate with granules;
FT                                dbSNP:rs137852648).
FT                                {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073190.
FT   VARIANT     334    334       I -> F (in CMT2D; shows a large reduction
FT                                in aminoacylation activity; demonstrates
FT                                a change in subcellular location pattern;
FT                                does not associate with granules).
FT                                {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073191.
FT   VARIANT     388    388       R -> Q (in dbSNP:rs17159287).
FT                                /FTId=VAR_054867.
FT   VARIANT     472    472       H -> R (in HMN5A; shows a large reduction
FT                                in aminoacylation activity; does not
FT                                complement the defect of the wild-type
FT                                gene in yeast).
FT                                {ECO:0000269|PubMed:17035524,
FT                                ECO:0000269|PubMed:24627108,
FT                                ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073192.
FT   VARIANT     554    554       D -> N (in CMT2D; demonstrates no change
FT                                in subcellular location pattern;
FT                                dbSNP:rs137852647).
FT                                {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073193.
FT   VARIANT     580    580       G -> R (in HMN5A; higher dimerization
FT                                stability; loss of activity; shows a
FT                                large reduction in aminoacylation
FT                                activity; dbSNP:rs28937323).
FT                                {ECO:0000269|PubMed:12690580,
FT                                ECO:0000269|PubMed:17035524,
FT                                ECO:0000269|PubMed:17545306,
FT                                ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_018721.
FT   VARIANT     635    635       S -> L (polymorphism; has no effect on
FT                                subcellular localization; results in
FT                                reduced activity; dbSNP:rs201358272).
FT                                {ECO:0000269|PubMed:17544401,
FT                                ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073194.
FT   VARIANT     652    652       G -> A (in CMT2D; shows a large reduction
FT                                in aminoacylation activity; demonstrates
FT                                a change in subcellular location pattern;
FT                                does not associate with granules).
FT                                {ECO:0000269|PubMed:25168514}.
FT                                /FTId=VAR_073195.
FT   CONFLICT      9     18       Missing (in Ref. 3; BAG58412).
FT                                {ECO:0000305}.
FT   CONFLICT    205    205       D -> G (in Ref. 3; BAG51964).
FT                                {ECO:0000305}.
FT   CONFLICT    530    530       M -> I (in Ref. 2; AAA86443).
FT                                {ECO:0000305}.
FT   CONFLICT    634    634       L -> S (in Ref. 3; BAG51964).
FT                                {ECO:0000305}.
FT   TURN         62     64       {ECO:0000244|PDB:5E6M}.
FT   HELIX        65     80       {ECO:0000244|PDB:5E6M}.
FT   TURN         81     83       {ECO:0000244|PDB:5E6M}.
FT   HELIX        95    112       {ECO:0000244|PDB:5E6M}.
FT   HELIX       121    130       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      133    136       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       139    141       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      148    150       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       152    168       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       170    173       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      182    185       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       186    191       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       194    197       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      199    208       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      211    213       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       214    227       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      229    231       {ECO:0000244|PDB:2Q5I}.
FT   HELIX       233    243       {ECO:0000244|PDB:2ZT5}.
FT   TURN        244    248       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       251    260       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      266    268       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      276    279       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      283    285       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      287    296       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      298    300       {ECO:0000244|PDB:2ZXF}.
FT   HELIX       301    305       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       308    314       {ECO:0000244|PDB:2ZT5}.
FT   TURN        315    317       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      321    330       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       339    341       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      344    355       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       357    359       {ECO:0000244|PDB:4KQE}.
FT   HELIX       365    367       {ECO:0000244|PDB:2ZT5}.
FT   TURN        368    370       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      372    376       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       378    382       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      388    391       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       392    397       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      400    402       {ECO:0000244|PDB:2PME}.
FT   HELIX       404    420       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       424    426       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      427    431       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       434    436       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      442    451       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      454    462       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       467    476       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      482    484       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       501    507       {ECO:0000244|PDB:4KQE}.
FT   HELIX       512    519       {ECO:0000244|PDB:4KQE}.
FT   HELIX       524    535       {ECO:0000244|PDB:4KQE}.
FT   STRAND      541    544       {ECO:0000244|PDB:4KQE}.
FT   STRAND      547    550       {ECO:0000244|PDB:4KQE}.
FT   STRAND      552    554       {ECO:0000244|PDB:4KQE}.
FT   STRAND      562    564       {ECO:0000244|PDB:2PMF}.
FT   TURN        565    567       {ECO:0000244|PDB:2PMF}.
FT   STRAND      568    570       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      573    580       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       581    592       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      593    595       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      597    600       {ECO:0000244|PDB:4KQE}.
FT   STRAND      603    605       {ECO:0000244|PDB:2ZT5}.
FT   TURN        609    611       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      615    621       {ECO:0000244|PDB:2ZT5}.
FT   TURN        625    627       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       628    640       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      645    647       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      650    652       {ECO:0000244|PDB:5E6M}.
FT   HELIX       654    663       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      668    672       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       674    677       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      679    681       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      683    688       {ECO:0000244|PDB:2ZT5}.
FT   TURN        689    691       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      694    698       {ECO:0000244|PDB:2ZT5}.
FT   TURN        699    701       {ECO:0000244|PDB:2ZT5}.
FT   HELIX       702    710       {ECO:0000244|PDB:2ZT5}.
FT   STRAND      712    714       {ECO:0000244|PDB:4KR3}.
FT   HELIX       716    722       {ECO:0000244|PDB:2ZT5}.
SQ   SEQUENCE   739 AA;  83166 MW;  E4C001CEBF985C59 CRC64;
     MPSPRPVLLR GARAALLLLL PPRLLARPSL LLRRSLSAAS CPPISLPAAA SRSSMDGAGA
     EEVLAPLRLA VRQQGDLVRK LKEDKAPQVD VDKAVAELKA RKRVLEAKEL ALQPKDDIVD
     RAKMEDTLKR RFFYDQAFAI YGGVSGLYDF GPVGCALKNN IIQTWRQHFI QEEQILEIDC
     TMLTPEPVLK TSGHVDKFAD FMVKDVKNGE CFRADHLLKA HLQKLMSDKK CSVEKKSEME
     SVLAQLDNYG QQELADLFVN YNVKSPITGN DLSPPVSFNL MFKTFIGPGG NMPGYLRPET
     AQGIFLNFKR LLEFNQGKLP FAAAQIGNSF RNEISPRSGL IRVREFTMAE IEHFVDPSEK
     DHPKFQNVAD LHLYLYSAKA QVSGQSARKM RLGDAVEQGV INNTVLGYFI GRIYLYLTKV
     GISPDKLRFR QHMENEMAHY ACDCWDAESK TSYGWIEIVG CADRSCYDLS CHARATKVPL
     VAEKPLKEPK TVNVVQFEPS KGAIGKAYKK DAKLVMEYLA ICDECYITEM EMLLNEKGEF
     TIETEGKTFQ LTKDMINVKR FQKTLYVEEV VPNVIEPSFG LGRIMYTVFE HTFHVREGDE
     QRTFFSFPAV VAPFKCSVLP LSQNQEFMPF VKELSEALTR HGVSHKVDDS SGSIGRRYAR
     TDEIGVAFGV TIDFDTVNKT PHTATLRDRD SMRQIRAEIS ELPSIVQDLA NGNITWADVE
     ARYPLFEGQE TGKKETIEE
//
